新股暗盤 | 再鼎醫藥-SB盤中一度漲超4%，頂頭槌狂賺250萬
uSMART友信智投9月25日消息，再鼎醫藥-SB上演"暗盤之戰"，平開高走，截至16:20分，再鼎醫藥-SB漲4.27%，報586港元，不計手續費，一手賺1200港元。
而押注再鼎醫藥-SB的乙組大佬們，再次上演華住集團-S般的"冷門奇蹟"。
uSMART曾在《新股配售》中統計過，與華住一樣，再鼎醫藥-SB的乙組獲配股數極高，乙頭獲配3600股，市值202.32萬港元，頂頭槌獲配150,600股，市值8463.72萬港元。
若再鼎醫藥-SB漲3%，扣除融資成本，乙頭約賺5.9萬港元，頂頭槌約賺247萬港元。
《新股配售 | 再鼎醫藥一手中籤率50%，公開認購3.43倍，國配6.9倍，港股比美股折價5.97%》
【再鼎醫藥-SB配售小結】
1、認購情況和華住相似：公開遇冷，認購倍數僅3.43倍，國配熱度不減，認購倍數約6.9倍，最終散戶的佔比僅8.5%，拋壓較小。
2、國配貨源高度集中：假設超額配股權獲悉數行使，前25名承配人合共鎖定84.1%的發行股份，貨源高度集中，最大承配人認購200萬股，市值高達11.24億港元，鎖定16.5%的發行股份。
3、有一定的折價"安全墊"：港股定價562港元，最新美股收盤價爲77.12美元，約爲597.68港元，港股定價比美股折價5.97%。已經上市的五隻二次上市中概股，4只港股比美股折價的均沒破發，僅港股比美股溢價的百勝中國-S首日破發。
4、乙組成本收益：與華住一樣，再鼎醫藥-SB的乙組獲配股數極高，乙頭獲配3600股，市值202.32萬港元，頂頭槌獲配150,600股，市值8463.72萬港元。
若再鼎漲3%，扣除融資成本(看"注"），乙頭約賺5.9萬港元，頂頭槌約賺247萬港元。但若再鼎破發，乙組的損失同樣慘重。
注：按計息日3天，按10倍槓桿，3.5%年化利息，100融資手續費計。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
